News Release Date : 11/19/2010
New Lung Cancer Study
STARS Protocol - International randomized phase III study to compare CyberKnife Stereotactic Radiotherapy with Surgical Resection in stage I non-small cell lung cancer.
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been the standard of care for operable early stage non-small cell lung cancer (NSCLC). Several studies have reported high local control and survival using Stereotactic Body RadioTherapy (SBRT) in stage I NSCLC patients. SBRT is now an acceptable treatment for medically inoperable patients with stage I NSCLC and patients with operable stage I lung cancer that are entered on clinical protocols.
The purpose of this study is to conduct a phase III randomized study to compare CyberKnife SBRT with surgery, the current standard of care for stage I operable NSCLC.
The sponsor for this study is Accuray Incorporated in collaboration with M.D. Anderson Cancer Center. If you know of someone who may be interested in the study, please call St. Mary's of Michigan's research staff at 907-8411 for further information.